Ann: Trading Halt, page-79

All cash payments to initiate the licence agreement will be funded through Imugene’s existing cash reserves with the option to make some payments in Imugene equity

I think that there is more to be said, so not overly bothered just yet.
After the last raise, it was stated by LC "that it will allow us to take advantage of any acquisitions that fit with IMU" .
So this T/O of another Bio is a logical bolt on for YF's work. IMO.
As it states in the other Ann, it is out of currently monies (approx A$145m in bank), it's only A$12M upfront.

So the TH Ann is left field IMO. e.g. a Nasdaq listing from memory is only about 15M, so again this could have been funded out of current monies.
This could be very juicy and interesting.
SP could go either IMO. But lets wait and see what LC/PH have to say.